Home › Premarket Biotech Digest: Tracking Gilead HCV Sales, Shire-Baxalta Deal, AstraZeneca Deal
 

Keywords :   


Premarket Biotech Digest: Tracking Gilead HCV Sales, Shire-Baxalta Deal, AstraZeneca Deal

2015-12-17 17:08:44| Biotech - Topix.net

The current consensus forecast for fourth quarter HCV sales is $2.81 billion. In the third quarter, U.S. HCV sales had totaled $3.23 billion.

Tags: sales deal tracking digest

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.06Tropical Storm Beryl Graphics
29.06Tropical Storm Beryl Forecast Discussion Number 4
29.06Tropical Storm Beryl Wind Speed Probabilities Number 4
29.06Tropical Storm Beryl Public Advisory Number 4
29.06Summary for Tropical Storm Beryl (AT2/AL022024)
29.06Tropical Storm Beryl Forecast Advisory Number 4
29.06Tropical Storm Beryl Public Advisory Number 3A
29.06Summary for Tropical Storm Beryl (AT2/AL022024)
More »